15 September 2026 Punjab Khabarnama Bureau : Ongoing measles outbreaks are creating a particular risk for adults living with autoimmune rheumatic diseases, as declining vaccination coverage can leave immunosuppressed patients vulnerable to a highly contagious infection.
A recent rheumatology review highlights the challenge faced by patients taking disease-modifying antirheumatic drugs (DMARDs), many of whom cannot simply receive the live-attenuated measles, mumps and rubella (MMR) vaccine while undergoing active immunosuppressive treatment.
Why Measles Is a Concern for Rheumatic Patients
Measles is extremely contagious, meaning outbreaks can spread rapidly when community immunity falls.
For people with autoimmune rheumatic conditions, the risk can be greater because both the disease itself and medicines used to control it may weaken immune responses.
The review notes that maintaining around 95% community vaccination coverage is important for preventing sustained measles transmission and protecting people who cannot safely rely on vaccination themselves.
MMR Vaccine Poses a Special Challenge
The MMR vaccine contains a live-attenuated virus. While it is routinely used to protect healthy people against measles, it is generally contraindicated during active treatment with several immunosuppressive therapies.
This creates a difficult situation for rheumatology patients who are not adequately protected against measles: they may need vaccination, but the timing has to be carefully coordinated with their treatment.
Treatment Timing Becomes Important
According to the review, patients who require measles vaccination may need carefully planned interruptions in certain immunosuppressive medicines.
The timing varies according to the drug. The review cites longer pauses for medicines such as methotrexate, leflunomide and systemic corticosteroids, while other therapies require different intervals. B-cell-depleting treatments such as rituximab can require a substantially longer interval before live vaccination is considered.
Such decisions cannot be made independently by patients because stopping immunosuppressive treatment can also trigger a flare of the underlying rheumatic disease.
Doctors Must Balance Two Risks
Rheumatologists therefore face a delicate balancing act.
On one side is the risk of measles infection in a patient with reduced immune protection. On the other is the possibility that interrupting treatment could cause the autoimmune disease to become active again.
The vaccination strategy therefore needs to be individualised according to the patient’s disease, current medicines, vaccination history and immune status.
Declining Community Immunity Raises the Risk
The problem becomes more serious when measles vaccination rates fall.
Even patients who cannot receive a live vaccine safely may be protected indirectly when vaccination coverage in their communities remains high.
When coverage drops below the level needed to interrupt transmission, these vulnerable patients can face increased exposure during outbreaks.
Household and Community Protection Matters
For immunosuppressed patients, protection is not limited to their own vaccination status.
Keeping family members and other close contacts appropriately vaccinated can reduce the likelihood that the virus will reach vulnerable individuals.
During an outbreak, avoiding exposure and following public-health guidance can become particularly important for patients receiving immune-suppressing therapies.
Measles Can Cause Serious Complications
Although many measles infections resolve without major complications, the disease can cause serious illness, including pneumonia and encephalitis.
The risk of severe disease is especially concerning in people whose immune systems are compromised, making prevention and early medical assessment important.
Doctors Need to Check Immunity
The latest review reinforces the importance of assessing measles immunity when managing patients with autoimmune rheumatic diseases.
Where possible, vaccination should ideally be considered before significant immunosuppression begins, allowing patients to build protection without having to interrupt essential treatment later.
A Wider Public-Health Warning
The issue extends beyond rheumatology.
Measles outbreaks demonstrate how falling vaccination coverage can affect people who have limited options for vaccination because of medical treatment. Maintaining strong community immunity therefore provides an additional layer of protection for vulnerable populations.
Need for Coordinated Care
The review highlights the need for rheumatologists, primary-care doctors and public-health teams to coordinate vaccination planning for patients with autoimmune diseases.
For patients receiving DMARDs or other immunosuppressive medicines, vaccination decisions should be made with their treating clinician rather than by stopping or changing medication independently.